



- (51) **International Patent Classification:**
A61K 35/48 (2006.01) *A61P 11/00* (2006.01)
- (21) **International Application Number:**
PCT/US2013/041002
- (22) **International Filing Date:**
14 May 2013 (14.05.2013)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
13/471,095 14 May 2012 (14.05.2012) US
- (71) **Applicant:** DEPUY SYNTHES PRODUCTS, LLC.
[US/US]; 325 Paramount Drive, Raynham, Massachusetts
02767 (US).
- (72) **Inventor:** KIHM, Anthony J.; 7 Harrogate Circle, Princeton,
New Jersey 08540 (US).
- (74) **Agent:** FINAN, Therese M.; Venable LLP, P.O. Box
34385, Washington, District of Columbia 20043-9998
(US).
- (81) **Designated States** (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- with (an) indication(s) in relation to deposited biological
material furnished under Rule 13bis separately from the
description (Rules 13bis.4(d)(i) and 48.2(a)(viii))

[Continued on next page]

- (54) **Title:** hUTC MODULATION OF PRO-INFLAMMATORY MEDIATORS OF LUNG AND PULMONARY DISEASES AND DISORDERS




Figure 1

- (57) **Abstract:** This invention encompasses methods, pharmaceutical compositions, and kits, which utilize umbilical cord tissue-derived cells, for modulating (e.g. reducing) the production of pro-inflammatory mediators involved in the pathology of a lung disease, disorder, and/or injury in a patient having the lung disease, disorder, and/or injury. The invention also encompasses methods, pharmaceutical compositions, and kits, which utilize umbilical cord tissue-derived cells, for inhibiting the production of pro-inflammatory mediators involved in the pathology of a lung disease, disorder, and/or injury in a patient having the lung disease, disorder, and/or injury utilizing umbilical cord tissue-derived cells. In one embodiment, the umbilical cord tissue-derived cells are isolated from human umbilical cord tissue substantially free of blood, are capable of self-renewal and expansion in culture, lack the production of CD117 or CD45, and do not express hTERT or telomerase.



— with sequence listing part of description (Rule 5.2(a))